Alliance Global Partners Cuts GeoVax Labs (NASDAQ:GOVX) Price Target to $8.50

GeoVax Labs (NASDAQ:GOVX) had its price objective reduced by Alliance Global Partners from $15.00 to $8.50 in a report released on Tuesday morning, MarketBeat.com reports. They currently have a buy rating on the stock.

Separately, D. Boral Capital reaffirmed a “buy” rating and set a $18.00 price objective on shares of GeoVax Labs in a research note on Thursday, April 10th. Five investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $12.90.

GeoVax Labs Stock Down 8.1 %

Shares of GOVX stock opened at $0.83 on Tuesday. The stock has a market capitalization of $11.48 million, a PE ratio of -0.15 and a beta of 3.70. GeoVax Labs has a 52 week low of $0.73 and a 52 week high of $11.18. The firm has a 50 day moving average of $1.37 and a two-hundred day moving average of $1.95.

GeoVax Labs (NASDAQ:GOVX) last posted its earnings results on Thursday, March 27th. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.79) by $0.49. The business had revenue of $3.00 million during the quarter, compared to analysts’ expectations of $2.38 million. Analysts expect that GeoVax Labs will post -4.49 EPS for the current fiscal year.

Hedge Funds Weigh In On GeoVax Labs

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Virtu Financial LLC acquired a new stake in GeoVax Labs in the 3rd quarter valued at about $97,000. Citadel Advisors LLC acquired a new stake in shares of GeoVax Labs during the fourth quarter valued at $104,000. Northern Trust Corp purchased a new stake in GeoVax Labs in the 4th quarter worth approximately $29,000. Finally, Geode Capital Management LLC increased its stake in GeoVax Labs by 59.0% in the fourth quarter. Geode Capital Management LLC now owns 90,139 shares of the company’s stock valued at $223,000 after purchasing an additional 33,440 shares during the last quarter. 6.09% of the stock is owned by institutional investors and hedge funds.

About GeoVax Labs

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.